David R. Bauer
Lawyers
Filters
Biodesix $55 million follow-on offering
The common stock is listed on the Nasdaq Global Market
Stoke Therapeutics $125 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Select Market
AnHeart Therapeutics acquisition by Nuvation Bio
We are advising AnHeart Therapeutics on the acquisition
MicroStrategy $603.75 million convertible notes offering
The convertible notes are due 2031
REGENXBIO $140 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
MicroStrategy $800 million convertible notes offering
The convertible notes are due 2030
iRhythm Technologies $661.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
Tandem Diabetes Care $316.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029
TruArc Partners acquisition of Meyer Laboratory and $179 million financing
We advised TruArc Partners on the acquisition and related financing arrangements
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches